Nectin-4 Emerges as a Therapeutic Target in Urothelial Carcinoma and Beyond
January 2nd 2022Most ongoing clinical trials exploring nectin-4 as a target involve studies of enfortumab vedotin and its potential synergy with immune checkpoint inhibitors in bladder cancer, while several other early-phase studies are testing novel agents in solid tumors.
Novel Combination Looks to Capitalize on Synergy of B7-H3/PD-1 Blockade
December 30th 2021The investigational monoclonal antibody enoblituzumab has demonstrated activity in preclinical studies and in combination with pembrolizumab in phase 1/2 studies in patients with checkpoint inhibitor–naïve head and neck squamous cell carcinoma and non–small cell lung cancer.
Abemaciclib Becomes First Agent of its Kind Approved for Adjuvant Treatment of Early Breast Cancer
December 28th 2021Stephen Johnston, MD, PhD, provides insight on the effect the approval of the CDK4/6 inhibitor abemaciclib has for patients with early breast cancer and how it will advance investigative efforts in this space.
Novel Agents Shake Up Myelodysplastic Syndrome Treatment Landscape
December 27th 2021During a recent OncLive Peer Exchange®, a panel of hematologic cancer experts shared their insights on the most recent FDA-approved agents for MDS, including luspatercept and decitabine/cedazuridine (Inqovi), both of which were approved in 2020.
It Is Time to Reexamine Control Arms in Phase 3 Trials
December 23rd 2021Maurie Markman, MD on strategies to appropriately evaluate small but clinically relevant patient subsets for whom traditional phase 3 randomized clinical trials are difficult, if not impossible, to complete in a realistically timely manner.